ODYY · XBRL financial data
Odyssey Health financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ODYY's year ends in late July)
| In thousands of dollars | Jul 31, 2021 | Jul 31, 2022 | Jul 31, 2023 | Jul 31, 2024 | Jul 31, 2025 | Jul 31, 2026 |
|---|---|---|---|---|---|---|
| Research and development | 1,633 | — | — | 55 | 0 | 0 |
| General and administrative | 6,421 | 6,790 | 2,122 | 1,507 | 1,021 | 913 |
| Operating income (loss) | (15,861) | (8,107) | (5,314) | 14,261 | (1,021) | (913) |
| Interest expense | 1,072 | 836 | 614 | 518 | 253 | 1,583 |
| Other income (expense) | — | — | 9 | 9 | (10) | (10) |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (16,883) | (8,444) | (5,919) | (842) | (1,743) | (5,730) |
| Earnings per share, basic USD per share | (0.18) | (0.09) | (0.07) | (0.01) | (0.02) | (0.05) |
| Earnings per share, diluted USD per share | (0.18) | (0.09) | (0.07) | (0.01) | (0.02) | (0.05) |
| Weighted average shares, basic thousands of shares | 93,734 | 88,995 | 82,677 | 97,064 | 104,710 | 108,323 |
| Weighted average shares, diluted thousands of shares | 93,734 | 88,995 | 82,677 | 97,064 | 104,710 | 108,323 |
Balance sheet
CSVFiscal years (ODYY's year ends in late July)
| In thousands of dollars | Jul 31, 2021 | Jul 31, 2022 | Jul 31, 2023 | Jul 31, 2024 | Jul 31, 2025 | Jul 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 557 | 73 | 37 | 2 | 19 | 122 |
| Prepaid and other current assets | 54 | 454 | 92 | 32 | 31 | 25 |
| Total current assets | 610 | 526 | 406 | 57 | 50 | 148 |
| Property and equipment, net | 0 | 0 | — | — | — | — |
| Total assets | 611 | 570 | 456 | 586 | 50 | 148 |
| Accounts payable | 1,225 | 1,550 | 1,798 | 1,276 | 1,615 | 712 |
| Accrued liabilities | — | 14 | 14 | — | — | — |
| Total current liabilities | 3,378 | 5,213 | 6,612 | 5,920 | 7,004 | 12,278 |
| Total liabilities | 3,378 | — | — | — | — | — |
| Accumulated deficit | (45,734) | (54,178) | (60,097) | (61,003) | (62,746) | (68,476) |
| Total stockholders' equity | (2,767) | (4,644) | (6,156) | (5,334) | (6,955) | (12,130) |
| Total liabilities and equity | 611 | 570 | 456 | 586 | 50 | 148 |
| Common shares outstanding (cover page) thousands of shares | 91,016 | 71,994 | 81,734 | 96,710 | 99,854 | 110,219 |
Cash flows
CSVFiscal years (ODYY's year ends in late July)
| In thousands of dollars | Jul 31, 2021 | Jul 31, 2022 | Jul 31, 2023 | Jul 31, 2024 | Jul 31, 2025 | Jul 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (16,883) | (8,444) | (5,919) | (842) | (1,743) | (5,730) |
| Stock-based compensation | — | — | 2,820 | 578 | 108 | 5 |
| Net cash from operating activities | (3,423) | (3,176) | (1,475) | (1,215) | (347) | (1,046) |
| Net cash from investing activities | 0 | — | (10) | 1,000 | 70 | 0 |
| Proceeds from issuing equity | 2,936 | 2,469 | 580 | 56 | 0 | — |
| Net cash from financing activities | 3,917 | 2,737 | 1,449 | 181 | 294 | 1,150 |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Odyssey Health | 122 | not reported | (160)* | 110.2M | 0.8 quarters | 10-KJul 31, 2026 |
| Autonomix Medical | 3,460 | 0 | (3,544) | 971,043 | 1.0 quarters | 10-QJun 30, 2026 |
| Sonoma Pharmaceuticals | 5,338 | 6,406 | (649) | 4.8M | 8.2 quarters | 10-QJun 30, 2026 |
| Family Office of America | 637 | 533 | 149* | 30.8M | — | 10-QJun 30, 2026 |
| Adm Tronics Unlimited | 223 | not reported | (33) | 67.6M | 6.8 quarters | 10-QJun 30, 2026 |
| Aethlon Medical | 4,934 | not reported | (1,897) | 711,136 | 2.6 quarters | 10-QJun 30, 2026 |
| Glucotrack | 1,124 | not reported | (3,616)* | 10.6M | 0.3 quarters | 10-QJun 30, 2026 |
| Bone Biologics | 6,088 | not reported | (532)* | 3.4M | 9.8 quarters | 10-QSep 30, 2026 |
| SeaStar Medical Holding | 6,959 | 615 | (2,994)* | 4.4M | 2.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.